A compound represented by general Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: R 1 is hydrogen, halogen, nitro, amino, hydroxyl, C 1 -C 12 alkyl, C 1 -C 6 alkoxyl, C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, hydroxymethyl, or aminomethyl; R2 is -NR 4 R 5 , wherein R 4 and R 5 are independently selected from a group consisting of hydrogen, C 1 -C 6 alkyl and C 1 -C 6 haloalkyl; or R 4 , R 5 and the nitrogen atom bonded to them form a saturated or unsaturated 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from a group consisting of NR 6 , O and S, wherein the heterocyclic ring is optionally substituted with hydroxyl, halogen, nitro, amino or C 1 -C 6 alkyl, wherein R 6 is hydrogen, hydroxyl, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl; R3 is hydrogen, halogen, nitro, amino, hydroxyl, C 1 -C 12 alkyl, C 1 -C 6 alkoxyl, C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, hydroxymethyl, aminomethyl or -COR a ; R a is OH or NR 7 R 8 , wherein R 7 and R 8 are independently selected from a group consisting of hydrogen, C 1 -C 6 alkyl optionally substituted with one or more substituents selected from halogen or NR 9 R 10 , and C 1 -C 6 alkyl substituted with 3-(C 2 -C 6 alkynyl)-3H-diaziridinyl; or R 7 , R 8 and the nitrogen atom bonded to them form a 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from a group consisting of N, O and S, and optionally substituted with C 1 -C 6 alkyl; R 9 and R 10 are independently selected from a group consisting of hydrogen and C 1 -C 6 alkyl; or R 9 , R 10 and the nitrogen atom bonded to them form a 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from a group consisting of N, O and S; and X is NH or O, linked to the phenyl group on a para- or meta-position. R 1 is hydrogen, halogen, nitro, amino, hydroxyl, C 1 -C 12 alkyl, C 1 -C 6 alkoxyl, C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, hydroxymethyl, or aminomethyl; R2 is -NR 4 R 5 , wherein R 4 and R 5 are independently selected from a group consisting of hydrogen, C 1 -C 6 alkyl and C 1 -C 6 haloalkyl; or R 4 , R 5 and the nitrogen atom bonded to them form a saturated or unsaturated 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from a group consisting of NR 6 , O and S, wherein the heterocyclic ring is optionally substituted with hydroxyl, halogen, nitro, amino or C 1 -C 6 alkyl, wherein R 6 is hydrogen, hydroxyl, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl; R3 is hydrogen, halogen, nitro, amino, hydroxyl, C 1 -C 12 alkyl, C 1 -C 6 alkoxyl, C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, hydroxymethyl, aminomethyl or -COR a ; R a is OH or NR 7 R 8 , wherein R 7 and R 8 are independently selected from a group consisting of hydrogen, C 1 -C 6 alkyl optionally substituted with one or more substituents selected from halogen or NR 9 R 10 , and C 1 -C 6 alkyl substituted with 3-(C 2 -C 6 alkynyl)-3H-diaziridinyl; or R 7 , R 8 and the nitrogen atom bonded to them form a 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from a group consisting of N, O and S, and optionally substituted with C 1 -C 6 alkyl; R 9 and R 10 are independently selected from a group consisting of hydrogen and C 1 -C 6 alkyl; or R 9 , R 10 and the nitrogen atom bonded to them form a 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from a group consisting of N, O and S; and X is NH or O, linked to the phenyl group on a para- or meta-position. <EOS>